Repros Therapeutics (RPRX +3.3%) moves higher after providing a status update for the one year...


Repros Therapeutics (RPRX +3.3%) moves higher after providing a status update for the one year open label extension of its Phase II clinical study of Androxal, an oral therapy designed to treat low testosterone in men.

From other sites
Comments (1)
  • William Pike, CFA
    , contributor
    Comments (5) | Send Message
     
    Stock will lag due to other product problems in the past. But RPRX is a sleeper. My guess is 50% upside by summer and possible double by year end.
    28 Dec 2011, 09:41 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs